XML 72 R61.htm IDEA: XBRL DOCUMENT v3.8.0.1
Reportable Segments (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Segment Reporting Information [Line Items]          
Sales $ 240,531 $ 203,930 $ 682,839 $ 644,782  
Operating Income (Loss) [1] 10,448 20,064 20,630 55,040  
Restructuring Costs 2,749 305 12,417 6,303  
Business Combination, Acquisition Related Costs 7,445   8,587    
Assets 1,693,023   1,693,023   $ 1,233,082
Energy & Chemicals [Member]          
Segment Reporting Information [Line Items]          
Sales 46,588 [2] 23,711 126,473 [2] 122,865  
Operating Income (Loss) 329 [2] (5,736) (2,420) [2] 14,190  
Restructuring Costs 162 159 2,245 821  
Assets 782,553 [3]   782,553 [3]   172,494
Distribution & Storage [Member]          
Segment Reporting Information [Line Items]          
Sales 139,281 126,646 390,057 363,743  
Operating Income (Loss) 21,016 14,715 49,186 37,550  
Restructuring Costs 648 118 1,085 3,929  
Assets 679,350   679,350   631,715
BioMedical [Member]          
Segment Reporting Information [Line Items]          
Sales 54,662 53,573 166,309 158,174  
Operating Income (Loss) 9,539 20,916 [4] 24,387 38,120 [4]  
Restructuring Costs 516 0 4,527 521  
Assets 165,195   165,195   166,940
Corporate [Member]          
Segment Reporting Information [Line Items]          
Operating Income (Loss) (20,436) [5] (9,831) (50,523) [5] (34,820)  
Restructuring Costs 1,423 28 4,560 1,032  
Assets $ 65,925   $ 65,925   $ 261,933
Cost of Sales [Member]          
Segment Reporting Information [Line Items]          
Gain (Loss) Related to Litigation Settlement   15,145   15,145  
Selling, General and Administrative Expenses [Member]          
Segment Reporting Information [Line Items]          
Gain (Loss) Related to Litigation Settlement   $ 859   $ 376  
[1] Includes restructuring costs of $2,749 and $305 for the three months ended September 30, 2017 and 2016, respectively, and $12,417 and $6,303 for the nine months ended September 30, 2017 and 2016 respectively.
[2] Includes results from the Hudson and Hetsco acquisitions, which are included in the Company’s E&C segment. Refer to the Business Combinations note for further details.
[3] Includes assets acquired from the Hudson and Hetsco acquisitions, which are included in the Company’s E&C segment. Refer to the Business Combinations note for further details.
[4] During the third quarter of 2016, the Company recovered for breaches of representations and warranties primarily related to warranty costs for certain product lines acquired in the 2012 acquisition of AirSep Corporation under the related representation and warranty insurance. For the three months ended September 30, 2016, this reduced our BioMedical segment’s cost of sales by $15,145 and Corporate SG&A expenses by $859, net of associated legal fees. For the nine months ended September 30, 2016, this reduced our BioMedical segment’s cost of sales by $15,145 and Corporate SG&A expenses by $376, net of associated legal fees recorded in the first nine months of 2016.
[5] Includes acquisition-related costs of $7,445 and $8,587 for the three and nine months ended September 30, 2017, respectively.